PARP inhibitors seemed down for the count in 2011, after Sanofi’s iniparib failed in a phase III trial in triple- negative breast cancer and AstraZeneca’s olaparib suffered a setback in ovarian cancer. But as drug developers realized that iniparib was not a true PARP inhibitor, and adopted a more cautious clinical trial strategy, the class mounted a comeback. In the past 5 years the FDA has approved four PARP inhibitors, from AstraZeneca, Clovis, GlaxoSmithKline and Pfizer, most notably for ovarian and breast cancers in patients with BRCA mutations…

Para acessar a publicação na íntegra clique aqui

Fonte: 814 | NOVEMBER 2019 | volume 18 NEws in BRiEf www.nature.com/nrd